GU23 ASCO

文章预览

44 Months follow up data for 9ER cabo/nivo vs sunitinib in RCC. RR, PFS impressive & similar to previous cuts. OS relatively stable: HR 0.70. Tox remain ok. OS in good risk looks the same as sunitinib (HR-1) but RR higher for combo. Debate around good risk treatment is complex . The studies not be translated to OS benefit ,though ORR/PFS was good .Certainliy we are seeing this in NSCLC too. DrChoueiri @DanaFarber on a interrogation of biomarkers in CheckMate9ER at .  7 established GES signatures did not predict outcome stellar presentation from @_ShankarSiva,kidneycancer. Lots of key papers in l delineating role in multiple tx settings COSMIC313 cabo/ipi/nivo vs ipi/nivo in 1st  line RCC. ️ FU show continued strong PFS signal:HR 0.74.Exploratory analysis show benefit for triplet mainly in intermediate risk .This is not due to ️ drug exposure. Maybe VEGF treatment ️ active in poor risk .       BIONIKK 1y on-continue to show promise meanwhile in clinic-we continue to ………………………………